Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | tumor protein p53 | Starlite/ChEMBL | No references |
Rattus norvegicus | Inositol monophosphatase 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | carnitine O-palmitoyltransferase, putative | 0.0115 | 0 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0115 | 0 | 0.5 |
Schistosoma mansoni | choline o-acyltransferase | 0.0115 | 0 | 0.5 |
Onchocerca volvulus | 0.0115 | 0 | 0.5 | |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0115 | 0 | 0.5 |
Onchocerca volvulus | 0.0115 | 0 | 0.5 | |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0628 | 0.5941 | 1 |
Echinococcus multilocularis | carnitine O palmitoyltransferase 1, liver | 0.0628 | 0.5941 | 1 |
Echinococcus granulosus | tumor protein p63 | 0.0408 | 0.339 | 0.5706 |
Echinococcus granulosus | carnitine O palmitoyltransferase 1 liver | 0.0628 | 0.5941 | 1 |
Trypanosoma cruzi | choline/carnitine O-acyltransferase, putative | 0.0628 | 0.5941 | 1 |
Trypanosoma brucei | carnitine O-acetyltransferase, putative | 0.0115 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0979 | 1 | 1 |
Onchocerca volvulus | 0.0115 | 0 | 0.5 | |
Onchocerca volvulus | 0.0115 | 0 | 0.5 | |
Schistosoma mansoni | choline o-acyltransferase | 0.0115 | 0 | 0.5 |
Echinococcus multilocularis | tumor protein p63 | 0.0408 | 0.339 | 0.5706 |
Trypanosoma brucei | carnitine O-palmitoyltransferase II, putative | 0.0115 | 0 | 0.5 |
Leishmania major | choline/Carnitine o-acyltransferase-like protein | 0.0628 | 0.5941 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium. (Class of assay: confirmatory) [Related pubchem assays: 901 ] | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PUBCHEM_BIOASSAY: qHTS assay for re-activators of p53 using a Luc reporter. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504709] | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 28.1838 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Potency (functional) | = 89.1251 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.